Oxaliplatin
Product Images NDC 57277-001

9 FDA label images from Sanja Pharmaceuticals Company · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 57277-001). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanja Pharmaceuticals Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg Carton (100mg 20ml Carton Rev)

100 mg Carton (100mg 20ml Carton Rev)
Oxaliplatin Injection USP 100 mg/20 mL (5 mg/mL) sterile aqueous solution carton label. Manufactured in India by Alidac Pharmaceuticals Limited, Ahmedabad, Gujarat, for Sanja Pharmaceuticals Company USA. The label states it is for intravenous use only, preservative free, single-use vial, and highlights storage instructions along with the NDC 57277-002-10 and cytoxic agent warning.*
FDA Label Image

Bottle 50 mg (50mg 5ml Bottle Rev)

Bottle 50 mg (50mg 5ml Bottle Rev)
Oxaliplatin Injection, USP 50 mg per 10 mL (5 mg/mL) vial label by Sanja Pharmaceuticals Company, intended for intravenous use only. The label advises against mixing or adding to sodium chloride or chloride-containing solutions, and notes it is a single-use vial. The label includes storage instructions, lot number, expiration date, and manufacturer details.*
FDA Label Image

Figure 2 (DFS Kaplan-Meier)

Figure 2 (DFS Kaplan-Meier)
A survival curve graph comparing disease-free survival probability over 72 months between two treatment arms labeled FOLFOX4 and LV5FU2. The graph includes a legend with number of events and percentages for each arm, a hazard ratio with confidence interval, and a p-value from a stratified logrank test. The x-axis represents disease-free survival in months, and the y-axis represents probability from 0 to 1. Below the x-axis is a table showing the number of patients at risk at various time points for each treatment arm.*
FDA Label Image

Figure 3 (DFS Kaplan-Meie)

Figure 3 (DFS Kaplan-Meie)
A Kaplan-Meier survival curve showing Disease-Free Survival (DFS) probability over months for two treatment arms: FOLFOX4 and LV5FU2, both with DUKES C stage III patients. The graph includes hazard ratio and p-value from a logrank test, illustrating comparative DFS between the treatments.*
FDA Label Image

Figure 01 (Fig 01)

Figure 01 (Fig 01)
A treatment schedule chart illustrating dosing intervals for Oxaliplatin Injection, USP 85 mg/m², combined with Leucovorin 200 mg/m² and 5-FU infusion 600 mg/m² on Day 1 and Day 2. The timeline shows the timing of bolus and infusion doses over a 24-hour cycle for each day.*
FDA Label Image

Figure 4 – Kaplan-meier (Fig 04)

Figure 4 – Kaplan-meier (Fig 04)
A Kaplan-Meier survival curve chart showing percentage of patients surviving over 24 months. It compares median survival among three treatment groups involving Oxaliplatin Injection combined with 5-FU/LV, Oxaliplatin Injection combined with irinotecan, and irinotecan combined with 5-FU/LV. The chart includes median survival times in months for each group and displays statistical significance via a log rank test.*
FDA Label Image

Structure (Structure 01)

Structure (Structure 01)
Chemical structure of oxaliplatin, showing a platinum center coordinated with an oxalate ligand and a cyclohexane-1,2-diamine moiety.*
FDA Label Image

100 mg Vial (Vial 100mg Vial Rev)

100 mg Vial (Vial 100mg Vial Rev)
Label for Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) single-use vial by Sanja Pharmaceuticals Company. The label includes dosage strength, directions for intravenous use, storage instructions, warnings about dilution and additives, and manufacturer details. The container size is 20 mL for injection.*
FDA Label Image

Vial 50 mg (Vial 50mg Rev)

Vial 50 mg (Vial 50mg Rev)
Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) sterile aqueous solution by Sanja Pharmaceuticals Company. The label states it is for intravenous use only, preservative-free, and single-use vial. Manufactured in India by Alidac Pharmaceuticals Limited, with storage instructions to keep at 25°C and protect from light. The label includes warnings not to mix with sodium chloride solutions and advises discarding unused portions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.